Necrosis and angioinvasion predict adverse outcome in pancreatic neuroendocrine tumors after curative surgical resection: results of a single-center series
- PMID: 21927963
- DOI: 10.1007/s00268-011-1262-9
Necrosis and angioinvasion predict adverse outcome in pancreatic neuroendocrine tumors after curative surgical resection: results of a single-center series
Abstract
Background: The prediction of outcome in pancreatic neuroendocrine tumors (P-NETs) still represents a challenge. Several clinicopathologic parameters have been proposed to predict adverse outcome. The aim of this study was to evaluate the impact of tumor necrosis and angioinvasion on the outcome after curative R0 resection of P-NETs.
Methods: We reviewed our institutional experience over the last 30 years. A total of 82 patients with a mean age of 54 years (range 17-83 years) underwent surgical resection of P-NETs during the period from 1964 to 2006. There were 41 men and 41 women. The patients' outcomes after R0 surgical treatment were analyzed in relation to the presence or absence of tumor cell necrosis and angioinvasion as judged by histologic methods.
Results: The overall (n = 82) 5-year survival was 52.4% (± 6.0%). Forty-eight of the patients underwent a R0 resection successfully. These patients showed a 5-year survival of 59.04% (± 7.8%); the median survival was 101 ± 36 months. Necrosis status was documented on 47 of the R0 resected patients (97.9%). The survival median of patients with tumor cell necrosis was significantly shorter than those without necrosis (41 ± 25 vs. 173 ± 69 months, respectively, P = 0.006). The patients' mean 5-year survival was also significantly decreased (28.9 ± 15.0% vs. 68.5.6 ± 8.9%). Angioinvasion status was documented on 43 of the R0 resected patients (90.0%). The median survival of these patients was decreased from 173 ± 51 to 54 ± 18 months when angioinvasion was observed in the histological sections (P = 0.104). The patients' mean 5-year survival was also decreased from 69.2 ± 9.3% to 35.9 ± 14.0%.
Conclusions: Long-term survival of patients with P-NETs is influenced by various pathologic factors. Among our patients, there was not a significant difference in overall survival based on the diameter of the primary tumor or the lymph node status after R0 surgical resection. The presence of necrosis in the TNM and World Health Organization classification for pancreatic endocrine tumor was associated with significant poor overall survival in each classification category. Hence, necrosis represents an independent variable for poor prognosis.
Similar articles
-
Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group.Surgery. 2019 Mar;165(3):548-556. doi: 10.1016/j.surg.2018.08.015. Epub 2018 Sep 29. Surgery. 2019. PMID: 30278986 Free PMC article.
-
Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors.Pancreas. 2014 Oct;43(7):1003-8. doi: 10.1097/MPA.0000000000000153. Pancreas. 2014. PMID: 24945681
-
Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems.Scand J Gastroenterol. 2010 Aug;45(7-8):971-9. doi: 10.3109/00365521003782363. Scand J Gastroenterol. 2010. PMID: 20441530
-
Pancreatic surgery with vascular reconstruction in patients with locally advanced pancreatic neuroendocrine tumors.J Gastrointest Surg. 2013 Jul;17(7):1224-32. doi: 10.1007/s11605-013-2221-6. Epub 2013 May 14. J Gastrointest Surg. 2013. PMID: 23670519 Review.
-
Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review.ScientificWorldJournal. 2012;2012:357475. doi: 10.1100/2012/357475. Epub 2012 Dec 10. ScientificWorldJournal. 2012. PMID: 23304085 Free PMC article. Review.
Cited by
-
Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness.HPB (Oxford). 2014 Apr;16(4):304-11. doi: 10.1111/hpb.12139. Epub 2013 Aug 29. HPB (Oxford). 2014. PMID: 23991643 Free PMC article.
-
Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3.J Histochem Cytochem. 2017 Jul;65(7):399-405. doi: 10.1369/0022155417708186. Epub 2017 May 22. J Histochem Cytochem. 2017. PMID: 28651471 Free PMC article.
-
Impact of Regional Metastasis on Survival for Patients with Nonfunctional Pancreatic Neuroendocrine Tumors: A Systematic Review.Ann Surg Oncol. 2024 Aug;31(8):4976-4985. doi: 10.1245/s10434-024-15249-1. Epub 2024 Apr 23. Ann Surg Oncol. 2024. PMID: 38652199
-
[18F]FMISO PET in metastatic neuroendocrine tumours: a pilot study.Asia Ocean J Nucl Med Biol. 2025;13(2):117-125. doi: 10.22038/aojnmb.2025.83664.1611. Asia Ocean J Nucl Med Biol. 2025. PMID: 40585285 Free PMC article.
-
Infiltrative Growth Predicts the Risk of Recurrence After Surgery in Well-Differentiated Non-Functioning Pancreatic Neuroendocrine Tumors.Endocr Pathol. 2023 Mar;34(1):142-155. doi: 10.1007/s12022-022-09745-x. Epub 2022 Dec 24. Endocr Pathol. 2023. PMID: 36564582
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical